Sangamo Therapeutics Inc’s (NASDAQ: SGMO) Future In 2024

Sangamo Therapeutics Inc (NASDAQ:SGMO) shares, rose in value, with the stock price up by 4.92% to the previous day’s close as strong demand from buyers drove the stock to $0.61.

Actively observing the price movement in the last trading, the stock closed the session at $0.58. The value of beta (5-year monthly) was 1.44. Referring to stock’s 52-week performance, its high was $1.80, and the low was $0.29. On the whole, SGMO has fluctuated by -40.20% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Sangamo Therapeutics Inc currently standing at about $124.24 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 12, 2024 – Mar 16, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.21, which is expected to increase to -$0.08 for fiscal year -$0.5 and then to about -$0.25 by fiscal year 2025. Data indicates that the EPS growth is expected to be 66.20% in 2025, while the next year’s EPS growth is forecast to be 50.00%.

Analysts have estimated the company’s revenue for the quarter at $6.65 million, with a low estimate of $2 million and a high estimate of $11.3 million. According to the average forecast, sales growth in current quarter could jump down -95.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $45.88 million, representing a decrease of -74.00% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SGMO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SGMO currently trading nearly -22.75% and -21.75% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.63, while the 7-day volatility ratio is showing 11.42% which for the 30-day chart, stands at 13.58%. Furthermore, Sangamo Therapeutics Inc (SGMO)’s beta value is 1.36, and its average true range (ATR) is 0.11.

A comparison of Sangamo Therapeutics Inc (SGMO) with its peers suggests the former has fared considerably weaker in the market. SGMO showed an intraday change of 4.92% in last session, and over the past year, it shrunk by -65.34%%.

Data on historical trading for Sangamo Therapeutics Inc (NASDAQ:SGMO) indicates that the trading volumes over the past 10 days have averaged 2.67 million and over the past 3 months, they’ve averaged 2.38 million. According to company’s latest data on outstanding shares, there are 203.67 million shares outstanding.

Nearly 11.57% of Sangamo Therapeutics Inc’s shares belong to company insiders and institutional investors own 43.08% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.88 million shares as on Mar 15, 2024, resulting in a short ratio of 3.52. According to the data, the short interest in Sangamo Therapeutics Inc (SGMO) stood at 6.08% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 9.73 million. The stock has risen by 12.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SGMO stock heading into the next quarter.